Interference with MHC class I epitope trimming provides paradoxical protection from autoimmune diabetes

This study demonstrates that in the NOD mouse model of type 1 diabetes, ERAP deficiency paradoxically protects against the disease by altering T cell differentiation and epitope presentation, despite increasing the display of a key self-antigen, thereby highlighting the complex risks of therapeutically modulating ERAP activity in autoimmunity.

The Gist

Imagine your body is a highly secure fortress, and the immune system is the army of guards patrolling the walls. Their job is to spot intruders (like viruses) and destroy them. But sometimes, the guards get confused and start attacking the fortress itself. This is what happens in Type 1 Diabetes: the body's immune system mistakenly attacks the insulin-producing cells in the pancreas.

This paper investigates a specific "security protocol" called ERAAP. Think of ERAAP as a master chef in the kitchen of your cells. Its job is to chop up large protein scraps (antigens) into tiny, perfect-sized pieces (peptides) that fit into a display window (MHC class I) on the cell's surface. The immune guards look through these windows to decide: "Is this a friend or a foe?"

The Big Question

Scientists knew that if the "chef" (ERAAP) is too picky or makes mistakes, it can lead to autoimmune diseases. But they didn't know how. So, they decided to remove the chef entirely from a group of mice that are genetically programmed to get diabetes (NOD mice) to see what would happen.

The Surprising Twist

The researchers expected that without the chef, the guards would see fewer "bad guys" and the disease would get worse or stay the same. Instead, they found a paradoxical twist:

1. The "Chef" Was Actually Hiding the Enemy:
   In normal mice, the chef chopped up a specific "bad guy" piece (an insulin fragment) so thoroughly that it disappeared from the display window. The immune guards barely saw it.
   In the mice without the chef, this specific "bad guy" piece was actually more visible because it wasn't being chopped up. You would think this would make the guards attack harder.

2. The "Overexposure" Trick:
   Here is the magic part. Because the "bad guy" piece was so clearly visible to the immune system early on (specifically in the training center, the thymus), the immune system decided, "Oh, this is just a regular part of the body! Ignore it!"
   It's like showing a security guard a photo of a suspicious person so many times that the guard eventually thinks, "That's just a regular employee," and stops checking them. The immune system became tolerant to the insulin.

3. The Result: A Peaceful Fortress:
   Even though the "bad guy" was more visible, the mice without the chef got diabetes much later, and fewer of them got it at all.

   • The Guards Changed: The immune cells that did show up in the pancreas were different. Instead of being "angry attack dogs" (effector cells), they were more like "calm observers" (memory cells) or "peacekeepers" (regulatory cells).
   • The Transfer Test: When the scientists took the "angry" guards from normal mice and put them into the "chef-less" mice, the guards couldn't start a riot. They just couldn't get the job done.

The Takeaway for Humans

This study is a huge warning for doctors and drug developers.

• The Trap: We might think that blocking the "chef" (ERAAP) to stop it from making the right "bad guy" pieces would cure autoimmune diseases.
• The Reality: Blocking the chef might actually make the "bad guy" pieces more visible, which could accidentally teach the immune system to ignore them, OR it could cause chaos in other ways.

In this specific case, removing the chef accidentally taught the immune system to be peaceful. But the authors warn that this is a complex game of "Jenga." Pulling out one block (the enzyme) might make the tower stand for a while, but it could also make it collapse in a completely different way.

In short: Sometimes, making a problem more visible to the immune system doesn't make it worse; it can actually teach the system to let it go. This suggests that treating autoimmune diseases by tweaking these enzymes is tricky and needs to be done with extreme caution.

Technical Summary

1. Problem Statement

• Background: Polymorphisms in endoplasmic reticulum aminopeptidases (ERAAP in mice, ERAP1/2 in humans), which trim antigen precursors for MHC class I presentation, are genetically associated with various autoimmune diseases (e.g., ankylosing spondylitis, psoriasis, and potentially Type 1 Diabetes [T1D]).
• The Knowledge Gap: While the association is established, the mechanistic link between ERAP activity and the pathogenesis of autoimmune diseases remains unclear. Specifically, it is unknown whether inhibiting or altering ERAP activity would exacerbate or ameliorate autoimmune responses.
• Hypothesis: The authors sought to determine how the absence of ERAAP affects the development of spontaneous autoimmune diabetes in the Non-Obese Diabetic (NOD) mouse model, a system where a specific CD8+ T cell epitope (Insulin B15-23) is known to drive disease.

2. Methodology

The study utilized a combination of genetic engineering, immunological assays, and adoptive transfer models:

• Generation of Eraap-/- NOD Mice:
  • Instead of traditional backcrossing, the authors used CRISPR/Cas9 to directly knockout the Eraap gene in NOD zygotes.
  • Two sgRNAs targeted Exon 2, resulting in a homozygous founder with a 49 bp deletion, causing a frameshift and premature stop codon (truncation at amino acid 46).
• Phenotypic Analysis:
  • Diabetes Monitoring: Blood glucose and urine glucose were monitored in Eraap-/- and Wild-Type (WT) NOD mice up to 30 weeks.
  • Histology: Pancreata were analyzed for insulitis severity (infiltration of mononuclear cells) and islet architecture at 16 weeks.
• Adoptive Transfer Assays:
  • Effector T Cell Transfer: CD3+CD25-CD62L- (effector) T cells were sorted from Eraap-/- and WT spleens and transferred into Rag1-/- NOD recipients to test diabetogenic potential.
  • Bone Marrow Chimeras: Eraap-/- and WT NOD mice were irradiated and reconstituted with bone marrow from G9C8 transgenic mice. G9C8 T cells express a T-cell receptor (TCR) specific for the immunodominant Insulin B15-23 epitope.
• Functional Assays:
  • IFN-γ Release: G9C8 T cells were co-cultured with WT vs. Eraap-/- beta cells to measure recognition of the Insulin B15-23 epitope.
• Flow Cytometry:
  • Immune cell populations (CD4+, CD8+, B cells, Tregs) and their differentiation states (naïve, central memory, effector memory) were analyzed in pancreatic lymph nodes (PLN) and islet infiltrates.

3. Key Contributions & Results

A. Eraap Deficiency Protects Against Spontaneous Diabetes

• Disease Incidence: Eraap-/- NOD mice showed a significant delay and reduction in diabetes onset compared to WT controls.
  • Females: Onset delayed by 8 weeks; final incidence reduced from 70% (WT) to 49% (Eraap-/-).
  • Males: Onset delayed by 5 weeks; final incidence reduced from 26% (WT) to 8.6% (Eraap-/-).
• Histology: Eraap-/- mice exhibited attenuated insulitis (less severe infiltration) and a higher number of preserved islets compared to WT mice.

B. Paradoxical Enhancement of Epitope Presentation

• Mechanism of Recognition: Contrary to the expectation that trimming deficiency would reduce epitope presentation, Eraap-/- beta cells presented the Insulin B15-23 epitope more efficiently.
• Functional Proof: G9C8 T cells (specific for Insulin B15-23) released significantly more IFN-γ when stimulated by Eraap-/- beta cells than by WT beta cells. This confirms that ERAAP normally trims and destroys this specific epitope; its absence leads to increased surface presentation.

C. Paradoxical Protection in Adoptive Transfer Models

Despite the increased presentation of the pathogenic epitope, Eraap deficiency conferred protection in transfer models:

• Effector Transfer: Splenic effector T cells from Eraap-/- donors failed to transfer diabetes to Rag1-/- recipients, whereas WT effector cells induced 100% diabetes.
• Chimera Protection: Eraap-/- recipients reconstituted with G9C8 bone marrow (which should drive rapid disease via Insulin B15-23 recognition) were completely protected from diabetes. In contrast, WT recipients developed disease within 4 weeks.

D. Immunological Shifts in Islet Infiltrates

Flow cytometry of pancreatic islets revealed a distinct immune profile in Eraap-/- mice:

• Reduced Infiltration: Total numbers of CD45+ cells, CD4+, CD8+, and B cells were lower in Eraap-/- islets.
• Phenotypic Shift: There was a dramatic shift from Effector Memory (Tem) to Central Memory (Tcm) phenotypes (CD44+CD62L+).
  • The ratio of Tem/Tcm was reversed, with a significant increase in Tcm and naïve T cells.
• Regulatory T Cells: There was an increased percentage of CD4+CD62L+CD25+ presumptive regulatory T cells (Tregs) within the islet infiltrates.

4. Significance and Conclusion

• The Paradox: The study reveals a counter-intuitive mechanism where increased presentation of a pathogenic self-epitope (Insulin B15-23) leads to disease protection.
• Proposed Mechanism: The authors hypothesize that enhanced presentation of the insulin epitope by thymic antigen-presenting cells (APCs) in Eraap-/- mice leads to more efficient central tolerance (deletion or anergy) of the specific autoreactive CD8+ T cells (like G9C8). Consequently, the peripheral pool of diabetogenic T cells is depleted or tolerized, preventing disease initiation despite the beta cells presenting the epitope more strongly.
• Therapeutic Implications:
  • The results challenge the simplistic view that inhibiting ERAP (to reduce autoimmunity) is beneficial.
  • They highlight that modulating ERAP activity in autoimmunity has complex, non-linear consequences that depend on the specific epitope and the stage of T cell development (thymic vs. peripheral).
  • Caution: Therapeutic strategies targeting ERAP1/2 for autoimmune diseases must be approached with extreme caution, as they could inadvertently alter the immunopeptidome in ways that either fail to protect or potentially exacerbate disease through mechanisms not yet fully understood.

In summary, this paper demonstrates that in the context of T1D, the loss of ERAAP activity alters the immunopeptidome to enhance the presentation of a key autoantigen, which paradoxically promotes central tolerance and protects against spontaneous and transferred autoimmune diabetes.